Inactive Instrument

News STALLERGENES

Stocks

FR0000065674

Biotechnology & Medical Research

End-of-day quote Euronext Paris
- ^EUR	-

14-10-22

DBV TECHNOLOGIES : French developer of 'peanut allergy patch' makes U.S. debut

RE

All News

Mentions Relevance

16-02-22	STALLERGENES : GREER ANNOUNCES ITS 2016 FINANCIAL CALENDAR	PU
16-02-10	STALLERGENES : MICHELE ANTONELLI APPOINTED PRESIDENT OF STALLERGENES SAS & EXECUTIVE VP HEAD OF EUROPE & ROW	PU
16-02-10	STALLERGENES : MICHELE ANTONELLI APPOINTED PRESIDENT OF STALLERGENES SAS AND EXECUTIVE VP, HEAD OF EUROPE & REST OF WORLD	PU
16-02-10	STALLERGENES : MICHELE ANTONELLI APPOINTED PRESIDENT OF STALLERGENES SAS AND EXECUTIVE VICE PRESIDENT, HEAD OF EUROPE & REST OF WORLD	PU
16-02-01	STALLERGENES : GREER ANNOUNCES RESUMPTION OF MANUFACTURING AT ITS ANTONY PLANT	PU
16-02-01	STALLERGENES : TIBOR NEMES APPOINTED GLOBAL HEAD OF TECHNICAL OPERATIONS	PU
15-12-07	STALLERGENES : RECALL OF ALLERGY IMMUNOTHERAPY PRODUCTS	PU
15-11-19	STALLERGENES : ANNOUNCES THE LAUNCH OF ACTAIR® IN JAPAN	PU
15-11-10	STALLERGENES : Michele Antonelli appointed as Executive Vice President, Head of International Operations	PU
15-11-10	STALLERGENES : Introducing a new global allergy company	PU
15-11-10	STALLERGENES : Ares Allergy Holdings plc becomes Stallergenes Greer plc	PU
15-11-10	STALLERGENES : Development of our House Dust Mite sublingual immunotherapy tablet	PU
15-06-08	Stallergenes : is pleased to see the mobile allergen exposure chamber at the 2015 EAACI congress, Barcelona	PU
14-10-24	Stallergenes : continues its international expansion with the opening of an affiliate in Canada.	PU
14-10-23	Stallergenes : sales reach €45.7 million in Q3 2014; Oralair® achieves market leadership in France; Continued expansion of international markets (up 33%)	PU
14-07-24	STALLERGENES : Half-year revenues and results	PU
14-07-08	Stallergenes : welcomes Fleur Pellerin, Secretary of State for Foreign Trade to its principal site in Antony, Hauts-de-Seine, France.	PU
14-06-06	Stallergenes : to be present at the 3rd annual Citi European healthcare conference on June 20, 2014	PU
14-05-08	STALLERGENES : Industrial consortium announces its support for GA²LEN’s developement of mobile environmental exposure chambers	PU
14-04-02	Stallergenes : announes FDA approval of Oralair®, the first sublingual immunotherapy tablet for the treatment of grass pollen allergy	PU
14-02-03	STALLERGENES : reports positive results in the phase II/III clinical trial of house dust mite immunotherapy tablets in Japan	PU
13-12-03	STALLERGENES : and ActoGeniX to develop together an innovative new class of oral treatments for allergy	PU
13-07-25	STALLERGENES : Half-Year Revenues and Results	BU
13-05-16	STALLERGENES : and DBV Technologies Enter into Partnership for the Development of Innovative Treatment of Respiratory Allergies	BU
13-04-22	STALLERGENES : Stallergenes' Q1 Revenue Stable (-0.4%) with Very Strong Growth of Oralair (+58%) and Continuous Expansion in International Markets (+39%)	BU

No results match your criteria

All News Broker Recommendations Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

Stock Market
Stocks
Stock
News STALLERGENES

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!